AstraZeneca in cancer viruses deal with Omnis Pharmaceuticals
LONDON, Jan 12 (Reuters) - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses.
The agreement will allow MedImmune to combine its experimental immunotherapy drugs with Omnis' virus programme, which is currently in initial Phase I clinical testing. Financial t#erms were not disclosed.
Oncolytic viruses are designed to target tumour cells with the killing potency of viruses.
(Reporting by Ben Hirschler, editing by Louise Heavens)
Terms and Privacy Policy